eng Science and Education Publishing American Journal of Medical Case Reports 2374-216X 2016-01-21 4 1 16 18 10.12691/ajmcr-4-1-5 AJMCR2016415 article Sabu John 1 Pramod Theetha Kariyanna drtkpram@gmail.com 2 Jonathan Marmur 2 Kamal Preet Singh 2 Mary Mallappallil 2 Division of Cardiology, Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A. Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A. Apixaban, a novel oral anticoagulant is approved for anticoagulation in non-valvular atrial fibrillation. Apixaban is found to be superior to warfarin in prevention of stroke and thromboembolism and is associated with lesser risk of bleeding. Peri-procedural discontinuation of apixaban is safe, but the risk of thrombosis exists. We here present a case of arterial thrombosis that lead to lower limb ischemia upon periprocedural discontinuation of apixaban. http://pubs.sciepub.com/ajmcr/4/1/5/ajmcr-4-1-5.pdf apixaban anticoagulation non-valvular atrial fibrillation thrombosis